PT-141 (bremelanotide) is a synthetic melanocortin analogue that acts on MC3R and MC4R receptors in the central nervous system to produce sexual arousal. Unlike phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, which work by dilating blood vessels in the periphery, PT-141 acts at the brain level — addressing the neurological and psychological components of arousal rather than the vascular mechanism alone.
The melanocortin system and arousal
Melanocortin receptors (MC1R–MC5R) are expressed throughout the central and peripheral nervous system and regulate a range of physiological functions including pigmentation, appetite, inflammation, and sexual function. MC3R and MC4R in the hypothalamus and limbic system are specifically implicated in sexual motivation and arousal. PT-141 activates these receptors directly, producing central nervous system-mediated arousal that does not depend on visual stimulation or the vascular response that PDE5 inhibitors target.
How PT-141 differs from PDE5 inhibitors
PDE5 inhibitors work by preventing the breakdown of cGMP, relaxing smooth muscle and dilating blood vessels — a purely vascular mechanism that is ineffective when the arousal signal from the brain is absent. PT-141 addresses the upstream signal rather than the downstream vascular response. This makes it effective in cases where PDE5 inhibitors fail — specifically in men with psychogenic or neurological components to performance concerns, where the vascular capacity is present but the central arousal signal is insufficient. It can also be used alongside CORE compounds for clients with both central and vascular components.
FDA approval and clinical status
PT-141 (bremelanotide) received FDA approval in 2019 under the brand name Vyleesi — approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. This is the only FDA-approved indication, though the compound has been used off-label in men based on consistent Phase 2 data demonstrating improved erectile function scores in populations including men who did not respond to PDE5 inhibitors. The biohacking and men's health community has extensively documented its use, with anecdotal and clinical reports consistent with the established mechanism.